EMA Authorised: SomaKit TOC (edotreotide) — Advanced Accelerator Applications

View source ↗

Summary

EMA authorised SomaKit TOC (edotreotide) for imaging neuroendocrine tumors; the product is designated an orphan medicine and is associated with radionuclide ima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• SomaKit TOC (edotreotide)

Snippet

Status: Authorised. Therapeutic area: Neuroendocrine Tumors;Radionuclide Imaging. MAH: Advanced Accelerator Applications. Decision date: 19/02/2026. Orphan medicine